300869 康泰医学
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.4118.34410.46920.79557.010
总资产报酬率 ROA (%)0.2704.7746.01714.42044.176
投入资产回报率 ROIC (%)0.2764.9306.26515.49331.466

边际利润分析
销售毛利率 (%)49.49657.58247.47749.07658.249
营业利润率 (%)3.73325.00130.79244.65151.001
息税前利润/营业总收入 (%)-0.15520.78923.74831.23549.848
净利润/营业总收入 (%)3.85622.19427.55238.77543.776

收益指标分析
经营活动净收益/利润总额(%)-13.93395.64173.11897.76395.327
价值变动净收益/利润总额(%)148.7217.24924.8840.3880.023
营业外收支净额/利润总额(%)7.032-0.3270.0540.5510.117

偿债能力分析
流动比率 (X)10.4165.3972.3001.4152.461
速动比率 (X)8.0194.3901.9130.9771.909
资产负债率 (%)31.83036.33848.34134.74325.217
带息债务/全部投入资本 (%)30.14534.34045.63331.354--
股东权益/带息债务 (%)230.402190.122117.616217.347531.953
股东权益/负债合计 (%)214.170175.196106.864187.830296.562
利息保障倍数 (X)0.037-5.032-3.363-2.286-41.120

营运能力分析
应收账款周转天数 (天)35.14348.34857.36833.2530.000
存货周转天数 (天)751.648507.615408.550273.4950.000